Augmentation of reduced folate carrier-mediated folate/antifolate transport through an antiport mechanism with 5-aminoimidazole-4-carboxamide riboside monophosphate

Molecular Pharmacology

Volumn 82, Issue 2, 2012, Pages 209-216

  Visentin, Michele ^a   Zhao, Rongbao ^a   Goldman, I David ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE PHOSPHATE; 5 IODOTUBERCIDIN; 5 METHYLTETRAHYDROFOLIC ACID; ANTIPORTER; FOLATE TRANSPORTER; FOLIC ACID ANTAGONIST; FOLINIC ACID; METHOTREXATE; PROTON COUPLED FOLATE TRANSPORTER; REDUCED FOLATE CARRIER;

ARTICLE; CELL TRANSPORT; CONTROLLED STUDY; HELA CELL; INTRACELLULAR TRANSPORT; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL;

AMINOIMIDAZOLE CARBOXAMIDE; DRUG SYNERGISM; FOLIC ACID ANTAGONISTS; HELA CELLS; HUMANS; PROTEIN TRANSPORT; REDUCED FOLATE CARRIER PROTEIN; RIBONUCLEOTIDES;

EID: 84863913513     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.078642     Document Type: Article

References (35)

1. Assaraf YG (2006) The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat 9:227-246.
2. Beckers A, Organe S, Timmermans L, Vanderhoydonc F, Deboel L, Derua R, Waelkens E, Brusselmans K, Verhoeven G, and Swinnen JV (2006) Methotrexate enhances the antianabolic and antiproliferative effects of 5-aminoimidazole-4- carboxamide riboside. Mol Cancer Ther 5:2211-2217.
3. Corradetti MN and Guan KL (2006) Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene 25:6347-6360.
4. Davies SP, Helps NR, Cohen PT, and Hardie DG (1995) 5′-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2Cα and native bovine protein phosphatase-2AC. FEBS Lett 377:421-425.
5. Diop-Bove NK, Wu J, Zhao R, Locker J, and Goldman ID (2009) Hypermethylation of the human proton-coupled folate transporter (SLC46A1) minimal transcriptional regulatory region in an antifolate-resistant HeLa cell line. Mol Cancer Ther 8:2424-2431.
6. Forrest LR and Rudnick G (2009) The rocking bundle: a mechanism for ion-coupled solute flux by symmetrical transporters. Physiology (Bethesda) 24:377-386.
7. Gadalla AE, Pearson T, Currie AJ, Dale N, Hawley SA, Sheehan M, Hirst W, Michel AD, Randall A, Hardie DG, et al. (2004) AICA riboside both activates AMP-activated protein kinase and competes with adenosine for the nucleoside transporter in the CA1 region of the rat hippocampus. J Neurochem 88:1272-1282.
8. Goldman ID (1971) A model system for the study of heteroexchange diffusion: methotrexate-folate interactions in L1210 leukemia and Ehrlich ascites tumor cells. Biochim Biophys Acta 233:624-634.
9. Goldman ID, Chattopadhyay S, Zhao R, and Moran R (2010) The antifolates: evolution, new agents in the clinic, and how targeting delivery via specific membrane transporters is driving the development of a next generation of folate analogs. Curr Opin Investig Drugs 11:1409-1423.
10. Isebaert SF, Swinnen JV, McBride WH, Begg AC, and Haustermans KM (2011) 5-Aminoimidazole-4-carboxamide riboside enhances effect of ionizing radiation in PC3 prostate cancer cells. Int J Radiat Oncol Biol Phys 81:1515-1523.
11. Kamen BA and Smith AK (2004) A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Adv Drug Deliv Rev 56:1085-1097.
12. Matherly LH and Hou Z (2008) Structure and function of the reduced folate carrier a paradigm of a major facilitator superfamily mammalian nutrient transporter. Vitam Horm 79:145-184.
13. McGuire JJ, Haile WH, and Yeh CC (2006) 5-Amino-4-Imidazolecarboxamide riboside potentiates both transport of reduced folates and antifolates by the human reduced folate carrier and their subsequent metabolism. Cancer Res 66:3836-3844.
14. Mitsos SE, Jolly SR, and Lucchesi BR (1985) Protective effects of AICAriboside in the globally ischemic isolated cat heart. Pharmacology 31:121-131.
15. Parkinson FE and Geiger JD (1996) Effects of iodotubercidin on adenosine kinase activity and nucleoside transport in DDT1 MF-2 smooth muscle cells. J Pharmacol Exp Ther 277:1397-1401.
16. Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, Sandoval C, Zhao R, Akabas MH, and Goldman ID (2006) Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 127:917-928.
17. Racanelli AC, Rothbart SB, Heyer CL, and Moran RG (2009) Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res 69:5467-5474.
18. Rattan R, Giri S, Singh AK, and Singh I (2005) 5-Aminoimidazole-4- carboxamide-1-β-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 280:39582-39593.
19. Sabina RL, Holmes EW, and Becker MA (1984) The enzymatic synthesis of 5-amino-4-imidazolecarboxamide riboside triphosphate (ZTP). Science 223:1193-1195.
20. Sharif KA and Goldman ID (2000) Rapid determination of membrane transport parameters in adherent cells. Biotechniques 28:926-928, 930, 932.
21. Swain JL, Hines JJ, Sabina RL, and Holmes EW (1982) Accelerated repletion of ATP and GTP pools in postischemic canine myocardium using a precursor of purine de novo synthesis. Circ Res 51:102-105.
22. Swinnen JV, Beckers A, Brusselmans K, Organe S, Segers J, Timmermans L, Vanderhoydonc F, Deboel L, Derua R, Waelkens E, et al. (2005) Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype. Cancer Res 65:2441-2448.
23. Tang YC, Williams BR, Siegel JJ, and Amon A (2011) Identification of aneuploidyselective antiproliferation compounds. Cell 144:499-512.
24. Thomas CB, Meade JC, and Holmes EW (1981) Aminoimidazole carboxamide ribonucleoside toxicity: a model for study of pyrimidine starvation. J Cell Physiol 107:335-344.
25. Unal ES, Zhao R, and Goldman ID (2009) Role of the glutamate 185 residue in proton translocation mediated by the proton-coupled folate transporter SLC46A1. Am J Physiol Cell Physiol 297:C66-C74.
26. Van Den Neste E, Van den Berghe G, and Bontemps F (2010) AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies. Expert Opin Investig Drugs 19:571-578.
27. Zhao R, Babani S, Gao F, Liu L, and Goldman ID (2000) The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate. Clin Cancer Res 6:3687-3695.
28. Zhao R, Diop-Bove N, Visentin M, and Goldman ID (2011) Mechanisms of membrane transport of folates into cells and across epithelia. Annu Rev Nutr 31:177-201.
29. Zhao R, Gao F, and Goldman ID (2002) Reduced folate carrier transports thiamine monophosphate: an alternative route for thiamine delivery into mammalian cells. Am J Physiol Cell Physiol 282:C1512-C1517.
30. Zhao R, Gao F, Hanscom M, and Goldman ID (2004a) A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier. Clin Cancer Res 10:718-727.
31. Zhao R, Gao F, Wang Y, Diaz GA, Gelb BD, and Goldman ID (2001) Impact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cells. J Biol Chem 276:1114-1118.
32. Zhao R, Hanscom M, Chattopadhyay S, and Goldman ID (2004b) Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: association with the presence of a secondary transport pathway. Cancer Res 64:3313-3319.
33. Zhao R, Matherly LH, and Goldman ID (2009) Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med 11:e4.
34. Zhao R, Qiu A, Tsai E, Jansen M, Akabas MH, and Goldman ID (2008) The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol 74:854-862.
35. Zhao R, Seither R, Brigle KE, Sharina IG, Wang PJ, and Goldman ID (1997) Impact of overexpression of the reduced folate carrier (RFC1), an anion exchanger, on concentrative transport in murine L1210 leukemia cells. J Biol Chem 272:21207-21212.